


The Power To Heal  
Pain-Causing Bone,  
Calcific And  
Soft Tissue.

Tenex Health TX® System

**TX-Bone** MicroTip



Distributed by:

# A Minimally Invasive Treatment Option For Tendinopathy, Bone Spurs And Other Conditions.



Tenex Health TX® System's latest innovation, TX-Bone MicroTip (TXB), goes beyond soft tissue to treat bony prominences and calcific tissue as well. For patients, this powerful device provides something previously unavailable - a minimally invasive, single-procedure approach to relieving pain at the source.

This safe and effective alternative to open surgery uses advanced ultrasonic technology and image guidance to enable precise cutting and removal of symptomatic soft tissue and bone, all performed percutaneously through a mini incision.

- Clinically effective in treating chronic diseased tendons in ≥85% of patients<sup>1\*</sup>
- Spares healthy soft tendon, while cutting and removing necrotic tissue<sup>2\*</sup>
- Well-tolerated in soft tissue, with less discomfort than open surgery<sup>3\*</sup>
- Return to activity is typically 6 - 8 weeks, 4 times faster than open surgery for soft tissue<sup>4\*</sup>

## A Single Procedure. Multiple Applications.


TXB utilizes easy-to-use technology to provide pain relief for a variety of chronic conditions all over the body. The simple outpatient procedure takes minutes under local anesthesia and requires only a small bandage instead of sutures. As a result, recovery is typically fast and free of both opioids and physical therapy. The procedure is covered by most insurance.

## Remove Bone Percutaneously.

Now you can treat the root cause of diabetic foot ulcers without entering or expanding the wound area. TXB allows you to subcutaneously remove underlying bony prominences and dense scar tissue, which helps enable a recurrence rate of less than 5%.<sup>5</sup>



Tenex Health TX® System Console



Diabetic foot ulcers



# Tenex Health TX<sup>®</sup> System Clinical Efficacy - Soft Tissue

Backed by over 8 years of clinical evidence for the TX1/TX2 MicroTips, the Tenex Health TX<sup>®</sup> System is helping patients achieve lasting healing less invasively. Data on file. Individual results may vary.\*

**89%**

**Knee, Achilles, Shoulder, Elbow**  
(KHANNA, ET AL 2013)  
Patient Improvement,  
18 Patients

**100%**

**Elbow**  
(KOH, ET AL 2013) (SENG ET AL 2016)  
Patient Satisfaction,  
Pain Relief Sustained At 3 Years,  
20 Patients

(BARNES, ET AL 2015)  
Significant Improvement In Pain  
By 6 Weeks,  
Sustained At 12 Months,  
19 Patients

**90%**

**GLUTEAL**  
(BAKER, MORREY 2020)  
Pain Improvement,  
29 Patients

**92%**

**ADDUCTOR LONGUS**  
(OSTROM, JOSEPH 2018)  
Pain Relief,  
Fast Recovery  
Under 6 Weeks,  
12 Patients

**94%**

**Knee**  
(ELATTRACHE, MORREY 2013)  
Patient Improvement,  
16 Patients,  
10 Returned To Prior Athletic Activity

**96%**

**PLANTAR FASCIA**  
(RAZDAN, ET AL 2018)  
Pain Relief By 6 Months,  
Would Recommend To A Friend,  
100 Patients

**92%**

**PLANTAR FASCIA**  
(PADEL 2015)  
3 Months-Resolution Of Symptoms  
24 Months-100% Achieved Resolution,  
12 Patients

**85%**

**Achilles Tendon**  
(CHIMENTI 2018)  
Long Term Pain Relief Sustained  
At 3.5 Years,  
34 Patients

**85%**


**Achilles Tendon**  
(FREED, ET AL 2019)  
Patient Success,  
25 Patients

**100%**


**Plantar Fibroma**  
(PADEL, DAYNES 2015)  
Resolution, No Recurrence At 2.5 Years,  
8 Patients




In treating diseased tendons and plantar fascia<sup>1</sup>



Return to activities in 6-8 weeks<sup>4</sup>  
Effective even after failed open surgical procedures<sup>7</sup>



Stimulates healing and promotes healthy tendon within 3 weeks, as shown in a rabbit model study<sup>6</sup>



An early treatment solution after patients fail conservative therapy. Patients without resolution after 3 months may need surgical intervention<sup>8</sup>

1. Baker CL, Mahoney JR. The Orthopaedic Journal of Sports Medicine 2020;8(3):1-8; Battista CT, et al. Tech in Hand and Upper Extrem Surg 2018;22:15-18.; Chimenti RL, et al. J Ultrasound Med 2019;39(6):1629-1635.; Elattrache NS, Morrey BF. Operat Tech Orthop 2013;23(2):98-103.; Freed L, et al. J Am Podiatr Med Assoc. 2019;109(1):1-8.; Khanna M, et al. Poster presented at: Annual Meeting American Academy of Phys Medicine & Rehabilitation 2013 Oct.; Koh JSB, et al. Am J Sports Med 2013;41(3):636-644.; Patel MM, et al. J Orthop Rheum 2015;2(2):1014.; Patel MM. Am J of Orthop 2015;44(3):107-110.; Razdan R, Vander Woude E. J Surg Procd Tech 2018;3(102):1-6.; Seng C, et al. Am J Sports Med 2016;44(2):504-510.; Yanish GJ, et al. Submitted, J Shoulder Elbow Surg, 2019 Apr.
2. Cimino WW, Bond LJ. Ultrasound Med Biol 1996;22(1):89-100.; O'Daly BJ, et al. J of Mater Process Tech 2008;200(1-3):38-58.
3. Yanish GJ, et al. Submitted for publication J Shoulder Elbow Surg, 2019 Apr.
4. Stuhlman CR, et al. Orthopedics 2016;39(6):e1028-e1035.; Yanish GJ, et al. Submitted, J Shoulder Elbow Surg, 2019 Apr.
5. Freed L. Diabetes 2020 Jun;69(Supplement 1).
6. Kamineni S, et al. J Orth Surg Res 2015;10:70:1-8.
7. Nanos KN, Malanga GA. PM R 2015;7(12):1300-1305.
8. Sanders TL, et al. Am J Sports Med 2015;43(5):1066-1071.

\* TXB has greater potential than TX1 or TX2 for faster and more tissue removal.

For more information on TXB, contact Bioventus:  
customer-care-international@bioventusglobal.com

Bioventus.com  
Tenexhealth.com  
Tricemedical.com



TENEX HEALTH | Tenex Health is now a part of Trice Medical

Distributed by:



Tenex Health, Inc, is the manufacturer of the Tenex Health TX<sup>®</sup> System. Bioventus LLC is an authorized international distributor for TRICE medical. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. Tenex Health, Tenex Health TX<sup>®</sup>, and the Tenex Health logo are trademarks of Tenex Health, Inc.

SMK-004459 04/22